Nadezhda Women's Health Hospital
7
5
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment
Role: lead
Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations
Role: lead
Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations
Role: lead
Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy
Role: lead
Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome
Role: lead
Reproductive Outcome After Sperm Selection for Intracytoplasmic Sperm Injection (ICSI) Using Zona Pellucida Proteins
Role: lead
Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response
Role: lead
All 7 trials loaded